Insider Selling: HCA Healthcare (NYSE:HCA) SVP Sells $4,126,931.60 in Stock

HCA Healthcare, Inc. (NYSE:HCA) SVP Jennifer Berres sold 8,020 shares of HCA Healthcare stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $514.58, for a total transaction of $4,126,931.60. Following the completion of the sale, the senior vice president owned 11,993 shares in the company, valued at approximately $6,171,357.94. This represents a 40.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

HCA Healthcare Trading Up 0.9%

HCA opened at $539.91 on Friday. HCA Healthcare, Inc. has a twelve month low of $295.00 and a twelve month high of $552.90. The stock has a market cap of $120.73 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 1.66 and a beta of 1.36. The business’s 50 day moving average is $482.80 and its 200-day moving average is $448.96.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.37 by $0.64. The company had revenue of $19.51 billion during the quarter, compared to analyst estimates of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.22 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 17th will be paid a $0.78 dividend. The ex-dividend date of this dividend is Tuesday, March 17th. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.6%. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.72. HCA Healthcare’s dividend payout ratio (DPR) is currently 10.15%.

Institutional Trading of HCA Healthcare

Large investors have recently added to or reduced their stakes in the company. Arete Wealth Advisors LLC purchased a new position in shares of HCA Healthcare during the fourth quarter valued at $269,000. Templeton & Phillips Capital Management LLC purchased a new position in HCA Healthcare during the 4th quarter valued at about $211,000. Transamerica Financial Advisors LLC lifted its position in shares of HCA Healthcare by 131.6% in the fourth quarter. Transamerica Financial Advisors LLC now owns 183 shares of the company’s stock worth $85,000 after purchasing an additional 104 shares in the last quarter. Parkside Financial Bank & Trust grew its position in HCA Healthcare by 21.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,449 shares of the company’s stock valued at $676,000 after purchasing an additional 258 shares in the last quarter. Finally, Winter & Associates Inc. purchased a new stake in HCA Healthcare in the 4th quarter worth approximately $217,000. 62.73% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about HCA Healthcare

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA’s share performance is strong on a year‑over‑year basis (shares up ~75% YoY), reinforcing momentum and investor confidence in the company’s results and outlook. Read More.
• Positive Sentiment: Zacks and other analysts highlight earnings growth and price strength; Zacks added HCA to focus coverage and raised FY‑2026 EPS estimates, supporting forward earnings momentum and valuation. Read More.
• Positive Sentiment: HCA raised its quarterly dividend (new quarterly payout announced), which narrows yield risk and is a modest positive for income‑oriented investors. Read More.
• Positive Sentiment: Large institutional flows and stake increases (e.g., Norges Bank, Pacer, Viking Global) point to strong institutional demand and provide technical/supportive buying pressure for the stock. Read More.
• Neutral Sentiment: HCA completed a 43‑hospital EHR rollout and is tracking success metrics — operational execution that can improve efficiency and integration over time but has a gradual, not immediate, earnings impact. Read More.
• Neutral Sentiment: Local expansion moves — HCA Houston Healthcare Tomball acquired Supreme Care ER and StoneSprings plans a freestanding ER conversion — small, market‑level capacity adds that could modestly lift volumes in those geographies. Read More.
• Neutral Sentiment: HCA sold ASC real estate — a financing/portfolio move that could free capital or change lease terms; impact depends on transaction use of proceeds. Read More.
• Negative Sentiment: Insider selling: two senior VPs disclosed multi‑million dollar sales (Christopher Wyatt sold ~$2.0M; Jennifer Berres sold ~$4.13M). Significant insider sales can create short‑term selling pressure or raise governance/portfolio‑rebalancing questions. Read More. Read More.
• Negative Sentiment: Zacks/other outlets flagged a downward revision to HCA’s Q1 EPS forecast, which can pressure near‑term expectations even as FY estimates were raised. Read More.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on HCA shares. Barclays increased their price target on HCA Healthcare from $494.00 to $551.00 and gave the company an “overweight” rating in a research note on Wednesday, January 28th. UBS Group lifted their target price on HCA Healthcare from $525.00 to $598.00 and gave the stock a “buy” rating in a report on Wednesday, January 28th. Sanford C. Bernstein set a $541.00 price objective on shares of HCA Healthcare in a research note on Monday, February 9th. Bank of America raised their target price on shares of HCA Healthcare from $430.00 to $470.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of HCA Healthcare in a research report on Monday, December 29th. Sixteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $523.27.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.